JADE BIOSCIENCES, INC.
NASDAQ: JBIO (Jade Biosciences, Inc.)
Kemas kini terakhir: 3 jam lalu21.51
-0.30 (-1.38%)
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Menaik |
| Biotechnology (Global) | Menaik | Menaik | |
| Stok | Jade Biosciences, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | -3.5 |
| Osilator Teknikal | 2.0 |
| Purata | -1.00 |
|
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade’s pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 0.04% |
| % Dimiliki oleh Institusi | 33.40% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Fairmount Funds Management Llc | 31 Mar 2026 | 4,553,494 |
| Bellevue Group Ag | 31 Mar 2026 | 3,501,502 |
| Venrock Adviser, Llc | 31 Mar 2026 | 3,220,364 |
| Baker Bros. Advisors Lp | 31 Mar 2026 | 1,641,137 |
| Remedium Capital Partners, Llc | 31 Mar 2026 | 1,577,750 |
| Versant Venture Management, Llc | 31 Mar 2026 | 1,525,820 |
| Avidity Partners Management Lp | 31 Mar 2026 | 1,400,708 |
| Samsara Biocapital, Llc | 31 Mar 2026 | 968,798 |
| Great Point Partners I Lp | 31 Mar 2026 | 964,462 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |